RGNT

Regentis Biomaterials Ltd.

Price Chart

Latest Quote

$1.29

+0.03 (+2.38%)

Current Price

Previous Close	$1.26
Open	$1.27
Day High	$1.42
Day Low	$1.25
Volume	23,718

Fetched: 2026-10-28T10:18:44

Stock Information

Shares Outstanding	7.02M
Total Debt	$29K
Cash Equivalents	$8.95M
Net Income	$-16.10M
Sector	Healthcare
Industry	Medical Instruments & Supplies
Market Cap	$9.06M
EPS (TTM)	$-2.46
Exchange	ASE

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$138K
Income	$-16.10M
Book/sh	$1.09
Cash/sh	$1.27

Financial Ratios

Quick Ratio	5.42
Current Ratio	5.62
Debt/Eq	0.38

Returns & Margins

ROA

-113.59%

Ownership

Insider Ownership	14.04%
Institutional Ownership	25.19%
Insider & Institutional transactions data not available

Valuation Ratios

P/B

1.18

Analyst Data

Recommendation	none
Target Price	$10.00

Technical Indicators

SMA20	$1.56
SMA50	$1.82
SMA200	$3.00
RSI	26.39
ATR	0.1099

Shares Float	4.26M
Short Float	0.24%
Short Ratio	0.19
Rel Volume	0.64

Performance History

Week	-12.24%
Month	-31.75%
Quarter	-27.53%
6 Months	-57.00%
YTD	-80.86%
10 Years	-82.80%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-10-27	$1.29	27,000
2026-10-26	$1.26	25,200
2026-10-23	$1.28	18,400
2026-10-22	$1.40	50,700
2026-10-21	$1.49	14,200
2026-10-20	$1.47	13,800
2026-10-19	$1.48	36,100
2026-10-16	$1.49	23,500
2026-10-15	$1.55	14,300
2026-10-14	$1.51	132,600
2026-10-13	$1.62	33,400
2026-10-12	$1.63	36,100
2026-10-09	$1.60	22,200
2026-10-08	$1.70	172,800
2026-10-07	$1.63	17,000
2026-10-06	$1.65	34,000
2026-10-05	$1.67	109,500
2026-10-02	$1.85	29,000
2026-10-01	$1.83	9,000
2026-09-30	$1.81	22,200
2026-09-29	$1.85	58,600
2026-09-28	$1.89	7,600

About Regentis Biomaterials Ltd.

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.

📰 Latest News

No news articles available at the moment. Check back later for updates on RGNT.

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$324,000	$171,000	$173,000	$0
Total Expenses	$8,619,000	$-932,000	$1,931,000	$1,407,000
Rent Expense Supplemental	$67,000	$69,000	$66,000	$84,000
Other Income Expense	$231,000	$559,000	$-6,000	$357,000
Net Non Operating Interest Income Expense	$-5,260,000	$3,310,000	$-2,195,000	$-399,000
Total Other Finance Cost	$4,936,000	$-3,481,000	$2,022,000	$399,000
Interest Expense Non Operating	$324,000	$171,000	$173,000	$0
Operating Expense	$8,619,000	$-932,000	$1,931,000	$1,407,000
General And Administrative Expense	$8,288,000	$712,000	$1,125,000	$436,000
Other Non Operating Income Expenses	-	$3,483,000	$-2,019,000	$-397,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-13,648,000	$4,801,000	$-4,132,000	$-1,449,000
Net Interest Income	$-5,260,000	$3,310,000	$-2,195,000	$-399,000
Normalized Income	$-13,879,000	$4,370,570	$-4,126,000	$-1,806,000
Net Income From Continuing And Discontinued Operation	$-13,648,000	$4,801,000	$-4,132,000	$-1,449,000
Total Operating Income As Reported	$-6,968,000	$932,000	$-1,931,000	$-1,407,000
Net Income Common Stockholders	$-13,692,000	$4,753,000	$-4,180,000	$-1,497,000
Net Income	$-13,648,000	$4,801,000	$-4,132,000	$-1,449,000
Net Income Including Noncontrolling Interests	$-13,648,000	$4,801,000	$-4,132,000	$-1,449,000
Net Income Continuous Operations	$-13,648,000	$4,801,000	$-4,132,000	$-1,449,000
Pretax Income	$-13,648,000	$4,801,000	$-4,132,000	$-1,449,000
Operating Income	$-8,619,000	$932,000	$-1,931,000	$-1,407,000
Per Share
Diluted EPS	$-24.16	$0.92	$-0.81	$-0.29
Basic EPS	$-24.16	$0.92	$-0.81	$-0.29
Other
Tax Effect Of Unusual Items	$0	$128,570	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-13,555,000	$4,413,000	$-3,953,000	$-1,806,000
Total Unusual Items	$231,000	$559,000	$-6,000	$357,000
Total Unusual Items Excluding Goodwill	$231,000	$559,000	$-6,000	$357,000
EBITDA (Bullshit earnings)	$-13,324,000	$4,972,000	$-3,959,000	$-1,449,000
EBIT	$-13,324,000	$4,972,000	$-3,959,000	$-1,449,000
Diluted Average Shares	$566,744	$5,179,378	$5,179,378	$5,179,378
Basic Average Shares	$566,744	$5,179,378	$5,179,378	$5,179,378
Diluted NI Availto Com Stockholders	$-13,692,000	$4,753,000	$-4,180,000	$-1,497,000
Otherunder Preferred Stock Dividend	$44,000	$48,000	$48,000	$48,000
Gain On Sale Of Security	$231,000	$559,000	$-6,000	$357,000
Research And Development	$331,000	$-1,644,000	$806,000	$971,000
Selling General And Administration	$8,288,000	$712,000	$1,125,000	$436,000
Other Gand A	$667,000	$643,000	$1,059,000	$352,000
Rent And Landing Fees	$67,000	$69,000	$66,000	$84,000
Salaries And Wages	$7,554,000	$0	$0	-

Fetched: 2026-10-25

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$4,744,000	$-41,104,000	$-45,905,000	$-42,061,000
Total Assets	$7,618,000	$482,000	$360,000	$1,717,000
Total Non Current Assets	$0	$0	$0	$0
Current Assets	$7,618,000	$482,000	$360,000	$1,717,000
Prepaid Assets	$10,000	$180,000	$7,000	$451,000
Receivables	$230,000	$73,000	$8,000	$26,000
Other Receivables	$230,000	$73,000	$8,000	$26,000
Cash Cash Equivalents And Short Term Investments	$7,378,000	$229,000	$345,000	$1,240,000
Cash And Cash Equivalents	$7,378,000	$229,000	$345,000	$1,240,000
Debt
Total Debt	$1,197,000	$4,945,000	$7,615,000	$6,472,000
Current Debt And Capital Lease Obligation	$1,197,000	$4,945,000	$210,000	-
Current Debt	$1,197,000	$4,945,000	$210,000	-
Other Current Borrowings	$1,197,000	$4,945,000	$210,000	-
Net Debt	-	$4,716,000	$7,270,000	$5,232,000
Long Term Debt And Capital Lease Obligation	-	-	$7,405,000	$6,472,000
Long Term Debt	-	-	$7,405,000	$6,472,000
Liabilities
Total Liabilities Net Minority Interest	$2,874,000	$41,586,000	$46,265,000	$43,778,000
Total Non Current Liabilities Net Minority Interest	$0	$35,098,000	$43,126,000	$41,169,000
Current Liabilities	$2,874,000	$6,488,000	$3,139,000	$2,609,000
Payables And Accrued Expenses	$1,659,000	$1,379,000	$872,000	$626,000
Payables	$266,000	$252,000	$354,000	$208,000
Accounts Payable	$266,000	$252,000	$353,000	$206,000
Derivative Product Liabilities	-	$0	$623,000	$685,000
Other Current Liabilities	-	$160,000	-	-
Current Deferred Liabilities	-	$0	$2,054,000	$1,981,000
Other Payable	-	-	$1,000	$2,000
Equity
Common Stock Equity	$4,744,000	$-41,104,000	$-45,905,000	$-42,061,000
Total Equity Gross Minority Interest	$4,744,000	$-41,104,000	$-45,905,000	$-42,061,000
Stockholders Equity	$4,744,000	$-41,104,000	$-45,905,000	$-42,061,000
Retained Earnings	$-55,794,000	$-42,146,000	$-46,947,000	$-42,815,000
Preferred Securities Outside Stock Equity	$0	$35,098,000	$35,098,000	$34,012,000
Other
Ordinary Shares Number	$5,179,378	$5,179,378	$4,929,378	$4,929,378
Share Issued	$5,179,378	$5,179,378	$4,929,378	$4,929,378
Tangible Book Value	$4,744,000	$-41,104,000	$-45,905,000	$-42,061,000
Invested Capital	$5,941,000	$-36,159,000	$-38,290,000	$-35,589,000
Working Capital	$4,744,000	$-6,006,000	$-2,779,000	$-892,000
Total Capitalization	$4,744,000	$-41,104,000	$-38,500,000	$-35,589,000
Additional Paid In Capital	$60,538,000	$1,042,000	$1,042,000	$754,000
Capital Stock	$0	$0	$0	$0
Common Stock	$0	$0	$0	$0
Pensionand Other Post Retirement Benefit Plans Current	$18,000	$4,000	$3,000	$2,000
Current Accrued Expenses	$1,393,000	$1,127,000	$518,000	$418,000
Current Deferred Revenue	-	$0	$2,054,000	$1,981,000

Fetched: 2026-10-25

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-1,375,000	$-641,000	$-1,220,000	$-1,504,000
Operating Activities
Operating Cash Flow	$-1,375,000	$-641,000	$-1,220,000	$-1,504,000
Cash Flow From Continuing Operating Activities	$-1,375,000	$-641,000	$-1,220,000	$-1,504,000
Operating Gains Losses	$6,882,000	$-531,000	$11,000	$-329,000
Financing Activities
Issuance Of Capital Stock	$8,224,000	$0	$0	-
Financing Cash Flow	$8,524,000	$525,000	$325,000	$0
Cash Flow From Continuing Financing Activities	$8,524,000	$525,000	$325,000	$0
Net Common Stock Issuance	$8,224,000	$0	$0	-
Common Stock Issuance	$8,224,000	$0	$0	-
Other
Repayment Of Debt	$0	$-325,000	$0	-
Issuance Of Debt	$300,000	$850,000	$325,000	$0
End Cash Position	$7,378,000	$229,000	$345,000	$1,240,000
Beginning Cash Position	$229,000	$345,000	$1,240,000	$2,744,000
Changes In Cash	$7,149,000	$-116,000	$-895,000	$-1,504,000
Net Issuance Payments Of Debt	$300,000	$525,000	$325,000	$0
Net Short Term Debt Issuance	$300,000	$75,000	$325,000	$0
Short Term Debt Payments	$0	$-325,000	$0	-
Short Term Debt Issuance	$300,000	$400,000	$325,000	$0
Net Long Term Debt Issuance	$0	$450,000	$0	$0
Long Term Debt Issuance	$0	$450,000	$0	$0
Change In Working Capital	$131,000	$-1,599,000	$709,000	$-123,000
Change In Other Current Assets	$-163,000	$-238,000	$462,000	$-106,000
Change In Payables And Accrued Expense	$294,000	$-1,361,000	$247,000	$-17,000
Change In Payable	$294,000	$-1,361,000	$247,000	$-17,000
Change In Account Payable	$14,000	$-101,000	$147,000	$-102,000
Other Non Cash Items	$5,260,000	$-3,312,000	$2,192,000	$397,000
Earnings Losses From Equity Investments	$7,042,000	$0	-	-
Gain Loss On Investment Securities	$-160,000	$-463,000	$-62,000	$-100,000
Net Foreign Currency Exchange Gain Loss	$0	$-68,000	$73,000	$-229,000
Net Income From Continuing Operations	$-13,648,000	$4,801,000	$-4,132,000	$-1,449,000

Fetched: 2026-10-25